Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
4.2
Journals
JoF
Special Issues
Antifungal Drugs, 2nd Edition
share announcement

Antifungal Drugs, 2nd Edition

A special issue of Journal of Fungi (ISSN 2309-608X). This special issue belongs to the section "Fungal Pathogenesis and Disease Control".

Deadline for manuscript submissions: closed (10 October 2023) | Viewed by 3637

Special Issue Editor

Prof. Dr. Susumu Kajiwara

E-Mail Website
Guest Editor
School of Life Science and Technolgy, Tokyo Institute of Technology, Yokohama, Japan
Interests: medical mycology; fungal infections; fungal immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Compared to many kinds of antibiotics for bacteria, antifungal drugs used for treating fungal infections in clinics and hospitals are limited. Antifungal drugs such as azoles, echinocandins, and polyenes are currently used for the treatment of invasive fungal infections caused by pathogens entering the human bloodstream, central nervous system, and organs such as liver and lungs, sometimes leading to life-threatening diseases to immunocompromised and immunosuppressed individuals. However, some of these antifungals are known to participate in drug–drug interactions and cause serious side effects. In addition, the antifungal and multidrug resistances of opportunistic fungi, including Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans, have increased and become a significant burden in clinical sites in the world. Recently, emerging fungal species such as C. auris were isolated, and some of their strains also show antifungal and multi-drug resistances.

The aim of this Special Issue is to highlight current research and the development of novel antifungal drugs and drug resistances in invasive fungal infection to humans.

Prof. Dr. Susumu Kajiwara
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antifungals
  • antifungal drug resistance
  • multidrug resistance of fungal pathogens
  • drug resistance of emerging fungi

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1710 KiB  
Article
Evaluation of Antifungal Selective Toxicity Using Candida glabrata ERG25 and Human SC4MOL Knock-In Strains
by Keiko Nakano, Michiyo Okamoto, Azusa Takahashi-Nakaguchi, Kaname Sasamoto, Masashi Yamaguchi and Hiroji Chibana
J. Fungi 2023, 9(10), 1035; https://doi.org/10.3390/jof9101035 - 20 Oct 2023
Viewed by 1382
Abstract
With only four classes of antifungal drugs available for the treatment of invasive systemic fungal infections, the number of resistant fungi is increasing, highlighting the urgent need for novel antifungal drugs. Ergosterol, an essential component of cell membranes, and its synthetic pathway have [...] Read more.
With only four classes of antifungal drugs available for the treatment of invasive systemic fungal infections, the number of resistant fungi is increasing, highlighting the urgent need for novel antifungal drugs. Ergosterol, an essential component of cell membranes, and its synthetic pathway have been targeted for antifungal drug development. Sterol-C4-methyl monooxygenase (Erg25p), which is a greater essential target than that of existing drugs, represents a promising drug target. However, the development of antifungal drugs must consider potential side effects, emphasizing the importance of evaluating their selective toxicity against fungi. In this study, we knocked in ERG25 of Candida glabrata and its human ortholog, SC4MOL, in ERG25-deleted Saccharomyces cerevisiae. Utilizing these strains, we evaluated 1181-0519, an Erg25p inhibitor, that exhibited selective toxicity against the C. glabrata ERG25 knock-in strain. Furthermore, 1181-0519 demonstrated broad-spectrum antifungal activity against pathogenic Candida species, including Candida auris. The approach of utilizing a gene that is functionally conserved between yeast and humans and subsequently screening for molecular target drugs enables the identification of selective inhibitors for both species. Full article
(This article belongs to the Special Issue Antifungal Drugs, 2nd Edition)
►▼ Show Figures

Figure 1

11 pages, 500 KiB  
Article
Antifungal Susceptibility Pattern of Candida glabrata from a Referral Center and Reference Laboratory: 2012–2022
by Supavit Chesdachai, Zachary A. Yetmar, Nischal Ranganath, Jenna J. Everson, Nancy L. Wengenack and Omar M. Abu Saleh
J. Fungi 2023, 9(8), 821; https://doi.org/10.3390/jof9080821 - 3 Aug 2023
Cited by 2 | Viewed by 1663
Abstract
The prevalence of invasive candidiasis caused by non-Candida albicans has rapidly increased. Candida glabrata (Nakaseomyces glabrata) is an important pathogen associated with substantial mortality. Our study examined the antifungal temporal susceptibility of C. glabrata and cross-resistance/non-wild-type patterns with other azoles [...] Read more.
The prevalence of invasive candidiasis caused by non-Candida albicans has rapidly increased. Candida glabrata (Nakaseomyces glabrata) is an important pathogen associated with substantial mortality. Our study examined the antifungal temporal susceptibility of C. glabrata and cross-resistance/non-wild-type patterns with other azoles and echinocandins. Laboratory data of all adult patients with C. glabrata isolated from clinical specimens at the Mayo Clinic, Rochester, from 2012 to 2022 were collected. Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used. We obtained 1046 C. glabrata isolates from 877 patients. Using CLSI and EUCAST breakpoints, 187 (17.9%) isolates and 256 (24.5%) isolates were fluconazole-resistant, respectively. Focusing on C. glabrata bloodstream infections, fluconazole-resistance ranged from 16 to 22%. Among those 187 fluconazole-resistant isolates, 187 (100%) and 184 (98.4%) isolates were also voriconazole and posaconazole non-wild-type, respectively, with 97 (51.9%) isolates deemed non-wild type for itraconazole. The fluconazole susceptibility pattern has not changed over the past decade. The proportion of fluconazole-resistant C. glabrata is relatively high, which could be due to the complexity of patients and fluconazole exposure. Itraconazole appears to be a compelling step-down therapy for fluconazole-resistant C. glabrata, given the high proportion of wild-type isolates. Further research to examine clinical outcomes is warranted. Full article
(This article belongs to the Special Issue Antifungal Drugs, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop